Listen

Press releases

Receive e-mail alerts

Interne link ProQR Doses First Patient in Phase 2/3 ILLUMINATE Trial of Sepofarsen for LCA10
april 15, 2019 om 11:00 AM UTC
Interne link ProQR to Present at the H.C. Wainwright Global Life Sciences Conference
april 01, 2019 om 11:00 AM UTC
Interne link ProQR spins out all Dystrophic Epidermolysis Bullosa activities into newly formed Wings Therapeutics created by EB Research Partnership
maart 26, 2019 om 08:01 PM UTC
Interne link ProQR traite le premier patient dans l’essai STELLAR de Phase 1/2 du QR-421a pour le syndrome d’Usher de type 2
maart 11, 2019 om 04:45 PM UTC
Interne link ProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2
maart 11, 2019 om 12:00 PM UTC
Interne link ProQR to Present at Cowen Health Care Conference
maart 05, 2019 om 12:00 PM UTC
Interne link ProQR Reports Fourth Quarter and Full Year 2018 Operating and Financial Results
februari 27, 2019 om 12:00 PM UTC
Interne link ProQR Announces “ProQR Vision 2023” Strategy at its Annual R&D Day
januari 29, 2019 om 01:30 PM UTC
Interne link ProQR Reaches Agreement with the FDA on Design of Phase 2/3 Pivotal Trial for Sepofarsen (QR-110) for Leber’s Congenital Amaurosis 10
januari 07, 2019 om 12:00 PM UTC
Interne link ProQR to Host R&D Day in New York on January 29
januari 03, 2019 om 12:00 PM UTC
Interne link ProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2
januari 02, 2019 om 12:00 PM UTC
Interne link ProQR Announces Extraordinary General Meeting of Shareholders
december 27, 2017 om 12:00 PM UTC
Interne link ProQR Receives Orphan Drug Designation from EMA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa
november 29, 2017 om 12:00 PM UTC
Interne link ProQR to Present at the Annual Piper Jaffray Healthcare Conference
november 21, 2017 om 12:00 PM UTC
Interne link ProQR Announces Results for the Third Quarter of 2017
november 20, 2017 om 12:00 PM UTC
Interne link ProQR Prices Approximately $20 Million Underwritten Public Offering and Concurrent Registered Direct Offering of Ordinary Shares
november 14, 2017 om 12:44 PM UTC
Interne link ProQR Announces Proposed Public Offering of Ordinary Shares
november 13, 2017 om 09:01 PM UTC
Interne link ProQR Doses First LCA 10 Patient in Clinical Trial of QR-110, ProQR’s Lead Program for Genetic Blindness
november 13, 2017 om 12:00 PM UTC
Interne link ProQR Appoints Thaddeus Dryja, M.D. to Scientific Advisory Board
november 09, 2017 om 12:00 PM UTC
Interne link ProQR to Present at EuroTIDES Conference
oktober 31, 2017 om 11:00 AM UTC
Interne link ProQR Announces Management Change and Key Promotions
oktober 26, 2017 om 11:00 AM UTC
Interne link ProQR Announces Presentations and Investor & Analyst Event at the North American Cystic Fibrosis Conference
oktober 24, 2017 om 11:00 AM UTC
Interne link ProQR to Present at the Chardan Inaugural Gene Therapy Conference
oktober 06, 2017 om 11:00 AM UTC
Interne link ProQR Announces Positive Top-Line Results from a Phase 1b Study of QR-010 in Subjects with Cystic Fibrosis
september 25, 2017 om 08:00 PM UTC
Interne link ProQR Presents in vivo Proof of Concept Data for the Axiomer® RNA Editing Platform Technology
september 21, 2017 om 11:05 AM UTC

Press releases

Interne link ProQR Doses First Patient in Phase 2/3 ILLUMINATE Trial of Sepofarsen for LCA10

Interne link ProQR to Present at the H.C. Wainwright Global Life Sciences Conference

Interne link ProQR spins out all Dystrophic Epidermolysis Bullosa activities into newly formed Wings Therapeutics created by EB Research Partnership

Interne link ProQR traite le premier patient dans l’essai STELLAR de Phase 1/2 du QR-421a pour le syndrome d’Usher de type 2

Interne link ProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2

Interne link ProQR to Present at Cowen Health Care Conference

Interne link ProQR Reports Fourth Quarter and Full Year 2018 Operating and Financial Results

Interne link ProQR Announces “ProQR Vision 2023” Strategy at its Annual R&D Day

Interne link ProQR Reaches Agreement with the FDA on Design of Phase 2/3 Pivotal Trial for Sepofarsen (QR-110) for Leber’s Congenital Amaurosis 10

Interne link ProQR to Host R&D Day in New York on January 29

Interne link ProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2

Interne link ProQR Announces Extraordinary General Meeting of Shareholders

Interne link ProQR Receives Orphan Drug Designation from EMA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa

Interne link ProQR to Present at the Annual Piper Jaffray Healthcare Conference

Interne link ProQR Announces Results for the Third Quarter of 2017

Interne link ProQR Prices Approximately $20 Million Underwritten Public Offering and Concurrent Registered Direct Offering of Ordinary Shares

Interne link ProQR Announces Proposed Public Offering of Ordinary Shares

Interne link ProQR Doses First LCA 10 Patient in Clinical Trial of QR-110, ProQR’s Lead Program for Genetic Blindness

Interne link ProQR Appoints Thaddeus Dryja, M.D. to Scientific Advisory Board

Interne link ProQR to Present at EuroTIDES Conference

Interne link ProQR Announces Management Change and Key Promotions

Interne link ProQR Announces Presentations and Investor & Analyst Event at the North American Cystic Fibrosis Conference

Interne link ProQR to Present at the Chardan Inaugural Gene Therapy Conference

Interne link ProQR Announces Positive Top-Line Results from a Phase 1b Study of QR-010 in Subjects with Cystic Fibrosis

Interne link ProQR Presents in vivo Proof of Concept Data for the Axiomer® RNA Editing Platform Technology